This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes

This study has been withdrawn prior to enrollment.
(No funding)
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00247026
First received: October 31, 2005
Last updated: April 10, 2007
Last verified: April 2007
October 31, 2005
April 10, 2007
April 2007
Not Provided
major hematologic improvement in any lineage
Same as current
Complete list of historical versions of study NCT00247026 on ClinicalTrials.gov Archive Site
  • Time to disease progression
  • Overall and progression-free survival
  • Cytogenetic response
  • • Time to disease progression
  • • Overall and progression-free survival
  • • Cytogenetic response
Not Provided
Not Provided
 
The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes
A Pilot Study to Determine the Clinical Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes
To determine the clinical effects of coenzyme Q10 and Curcumin in improving the cytopenias of patients with myelodysplastic syndromes. we propose to explore the efficacy of the natural compounds curcumin and CoQ10 in MDS because these two agents possess many of the effects that are desirable in MDS.
Not Provided
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Myelodysplastic Syndrome
Drug: curcumin; coenzyme q10
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
50
Not Provided
Not Provided

Inclusion Criteria:

  • MDS patients with RA, RARS or RAEB will be eligible for treatment with CoQ10 as long as their IPSS score ≤ 1.5.

Exclusion Criteria:

  • Pregnant women and nursing women will be excluded.
  • History of clinically significant liver or kidney disease.
  • ECOG>2
  • IPSS score >1.5
  • Poorly controlled diabetes mellitus, hypertension, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to the protocol.
Sexes Eligible for Study: All
16 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
 
NCT00247026
385-mds 1-HMO-CTIL
mds 1
Not Provided
Not Provided
Not Provided
Not Provided
Hadassah Medical Organization
Not Provided
Principal Investigator: moshe e gatt, dr Hadassah Medical Organization
Hadassah Medical Organization
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP